CSL Ltd makes $11.7 billion offer to acquire Vifor Pharma

14 December 2021

After a few of days speculation and rumors, Australia-headquartered biotech CSL Limited (ASX: CSL) today confirmed it has entered into a definitive agreement to acquire Switzerland-based Vifor Pharma (VTX: FIFoN), a specialty pharmaceutical company with leadership in iron deficiency, nephrology and cardio-renal therapies.

CSL has made an offer of $179.25 (167 Swiss francs) per share, payable in US dollars, a premium of 61% to Vifor’s unaffected closing price on December 1, for an aggregate equity value for Vifor Pharma of $ 11.7 billion/10.9 billion francs. The tender is currently expected to commence around January 18, 2022 and the transaction is expected to complete around mid-2022.

Vifor’s shares, which had already risen earlier this month on the basis of the rumors, were up 11.8% at 156.90 francs by late afternoon today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK